What is BPC-157?

BPC-157 is a synthetic pentadecapeptide (a chain of 15 amino acids) whose sequence is described as a partial sequence of body protection compound, a protein reported in human gastric juice. ^[9] The originating group in Zagreb described BPC as a gastric juice peptide of relative molecular mass 40,000, and BPC 157 as a 15-amino-acid fragment "thought to be essential for its activity". ^[1]

The name is literal. BPC stands for body protection compound, and 157 is the code the Zagreb group gave the fragment. Other names in the literature and databases are Bepecin, PL-14736 and PLD-116. ^[4] Papers from 2003 to 2007 describe the peptide as "in clinical trials for inflammatory bowel disease" under the PL codes, with the Croatian company Pliva named alongside them. ^[10][11] No results of those trials are indexed in PubMed as a clinical trial publication. ^[5]

The peptide you buy is made in a lab. The Chinese group that ran the 2022 pharmacokinetic study describes its material as made by solid-phase synthesis. ^[12] BPC-157 in 5mg vials is in stock with a batch certificate.

BPC-157 has no single identified receptor in the studies reviewed here. Published work describes activity on several signalling pathways, mostly in cell culture and rodents, and a 2019 review noted that the precise mechanisms still need to be understood. ^[13]

Four pathways recur in the literature:

1. FAK-paxillin. In rat Achilles tendon fibroblasts, a 2011 cell study reported faster outgrowth from tendon explants, better cell survival under hydrogen peroxide stress and more cell migration. It linked these to phosphorylation of FAK and paxillin, two proteins that anchor cells to their surroundings. ^[9]
2. Growth hormone receptor. The same Taiwanese group reported in 2014 that the growth hormone receptor was one of the most up-regulated genes in those fibroblasts, with downstream JAK2 activation when growth hormone was added. ^[14]
3. VEGFR2-Akt-eNOS. A 2017 study reported more new vessel formation in chick embryo membranes and endothelial tube assays, and higher VEGFR2 expression in human vascular endothelial cells and in rats with hind limb ischaemia. ^[15]
4. Nitric oxide. In isolated rat aorta, BPC-157 relaxed the vessel in a concentration-dependent way that nitric oxide blockers removed. The authors traced this to the Src-Caveolin-1-eNOS pathway. ^[16] A 2026 study repeated the finding in rings of human internal mammary artery left over from 12 bypass operations. ^[17]

The Zagreb group places these findings under one idea, "organoprotection": a stomach-derived peptide that protects many organs. ^[1] A compound reported to act in nearly every organ model, with no defined receptor, still needs a mechanism that independent labs can test.

BPC-157 is a linear, unmodified 15-residue peptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. All 15 residues are standard amino acids, and it carries no fatty acid chain.

The identifiers come from PubChem, ^[4] and the Zagreb group prints the same sequence with a molecular weight of 1419. ^[10] We checked each value against PubChem on 29 September 2026.

Anti-doping chemists identified BPC-157, with this sequence, in confiscated vials in 2017. ^[18] When you check a certificate, the mass spectrometry result should match a peptide of about 1419.5 g/mol.

Research on BPC-157 has examined rodent injury models, cell culture and three small human pilots, with no completed controlled human trial. A 2025 systematic review screened 544 articles published from 1993 to 2024 and included 36: 35 preclinical studies and 1 clinical study. ^[6] A 2026 review states there is no completed phase II clinical trial. ^[7]

The Zagreb group's 1993 summary already claimed that "practically all organ systems appear to benefit". ^[1] Every row above describes what one study reported for its own model. None of it is a claim about a research vial.

The BPC-157 literature is concentrated in one research group to a degree that is rare for a compound this widely discussed. We searched PubMed on 29 September 2026 for BPC-157 and its code names in titles and abstracts. The search returned 228 records. P. Sikiric of the University of Zagreb is an author on 174 of them, about 76%. ^[5]

The 54 records without him are mostly reviews, analytical chemistry and a handful of independent lab studies. The largest independent cluster is the Chang Gung University group in Taiwan, which produced the fibroblast, growth hormone receptor and vascular studies in the table. ^[9][15] A 2019 review from Loughborough University made the same point: over two decades, "only a handful of research groups have performed in-depth studies regarding this peptide". ^[13]

Most rodent results still await repetition by a lab with no link to the group that produced them.

The BPC-157 evidence does not show any effect in a controlled human trial, because none has been published. Four limits matter most.

1. No controlled human data. All three human studies lacked a control group. The knee study was a phone survey of past patients with no measurement tool, and the intravenous pilot had two participants. ^[20][22] A 2025 review concluded that "rigorous, large-scale trials are lacking". ^[2]
2. The human pilots share one first author and non-standard material. All three list E. Lee as first author and ran at private clinics, two of them named as in Florida. ^[22][21][20] A 2026 review counts fewer than 30 participants across the three pilots and says none used a standardised pharmaceutical preparation. ^[7] The interstitial cystitis pilot used material from a compounding pharmacy. ^[21]
3. Independent replication is thin. The 2026 rat study run by an Istanbul group found that BPC-157 improved tendon scores numerically, but the change did not reach statistical significance, while TB-500 did. ^[23]
4. A short half-life sits beside long reported effects. Plasma half-life in rats and dogs is under 30 minutes. ^[12] A 2026 review calls the gap between that and effects reported to last hours or days a "disconnect" still unexplained. ^[7]

The three published human pilots reported no adverse events, and none was designed to detect uncommon ones. In the intravenous pilot, 2 adults showed no measurable change in tested markers of the heart, liver, kidneys, thyroid or blood glucose, and neither participant reported a side effect. ^[22] In the interstitial cystitis pilot, 12 women received BPC-157 into the bladder wall during a single cystoscopy, no one dropped out and no adverse events were reported. ^[21] A 2025 review confirms that no adverse effects were reported across the three pilots. ^[2]

Animal and regulator data add more detail:

• Animal toxicology (2020). A Chinese group tested BPC-157 in mice, rats, rabbits and dogs. The single-exposure study showed no test-related effects. In repeated-exposure studies in dogs, creatinine fell at the highest level tested and returned to normal 2 weeks after exposure stopped. Local irritation was mild, and the study reported no genetic or embryo-fetal toxicity. ^[19]
• Systematic review (2025). Preclinical studies showed no adverse effects across several organ systems, and the authors found no clinical safety data. They listed unregulated manufacturing and contamination as possible sources of adverse effects. ^[6]
• TGA reports (2026). The TGA names BPC-157 among unapproved peptide products it has not evaluated. Reports it received for unapproved peptide products as a group include severe allergic reactions needing adrenaline and hospital care, and systemic inflammatory response syndrome. The TGA does not attribute these reports to a single compound. ^[24]

On the questions people ask most, liver, heart and blood pressure: the intravenous pilot tested liver and heart markers in 2 people and reported no measurable change. ^[22] No human study in our source set reports blood pressure values. The vessel-relaxing effect has been measured only in isolated rat aorta and human artery rings outside the body. ^[16][17]

BPC-157 is listed in Schedule 4 of the Poisons Standard (prescription only) and in Appendix D clause 5, which makes possession without authority an offence. Both entries are in the June 2026 Poisons Standard instrument (F2026L00633), which commenced on 1 June 2026. BPC-157 is item 5 in the clause 5 table, and its Schedule 4 entry carries the mark for Appendix D. ^[3]

No BPC-157 product is registered as a medicine in Australia. The TGA lists it among examples of unapproved peptide products that have not been evaluated for safety, quality or effectiveness. ^[24] Outside Australia, a 2025 review notes it has not been approved by the FDA or other regulators. ^[25]

For sport, the WADA 2026 Prohibited List, effective 1 January 2026, names BPC-157 as an example in class S0, non-approved substances, prohibited at all times. ^[8] One trap: a 2025 review stated that WADA did not currently list BPC-157. ^[25] The 2026 List names it directly, so older articles repeating that line are out of date. WADA revises the List every year, so check the current edition.

Scheduling is compound-specific, and state and territory law implements it. Our guide to Australian peptide law and the Poisons Standard explains Schedule 4, Appendix D and how they apply.

BPC-157 and TB-500 are both short synthetic peptides studied in tendon and soft-tissue models, and they differ in origin, length and evidence. BPC-157 is a 15-residue fragment of a gastric juice protein. TB-500 is a short synthetic fragment of thymosin beta-4, a 43-residue protein.

Scheduling for both comes from the June 2026 instrument, where TB-500 is item 35 in the Appendix D clause 5 table, ^[3] and both appear in the WADA 2026 index. ^[8]

One published rat study compares them head to head. In 2026, 32 rats with repaired Achilles tendons were split into control, BPC-157, TB-500 and combined groups. TB-500 reached statistical significance on load to failure and histology scores, BPC-157 did not, and the combination showed no added benefit over either peptide alone. ^[23] The full comparison is in BPC-157 vs TB-500. Both sit in our recovery research peptides range.

BPC-157 has no published stability study for lyophilised research material, so storage follows general peptide practice: sealed, cold, dry and dark. What the literature does report is stability in harsh conditions. The Zagreb group describes it as stable in human gastric juice, ^[11] a 2026 review calls that stability "unusual", ^[7] and an anti-doping lab found it stable in urine for at least 4 days. ^[18] None of those findings tells you how long a reconstituted vial keeps.

Once reconstituted, a peptide solution is far more exposed than the powder. Keep it refrigerated, protect it from light, avoid repeated freezing and thawing, and label the vial with the date, solvent and concentration in mg per mL.

On solvents, rat studies from the Zagreb group dissolved BPC-157 in saline with no carrier added, ^[10] and the intravenous pilot used normal saline. ^[22] We stock BAC Water (sterile water with 0.9% benzyl alcohol) in 3ml vials for A$8 for laboratory reconstitution. Our peptide reconstitution guide covers solvent choice and concentration arithmetic, and the peptide storage guide covers temperature, light and freeze-thaw.

Peptides Collective sells BPC-157 for laboratory research use only, in 5mg vials for A$81. Stock ships from Western Australia with tracking. BPC-157 also appears as a component in two of our stacks, the Wolverine Stack and KLOW, each with its own certificate.

Every batch is tested by an independent lab before it goes on sale. The certificate reports purity by HPLC and identity by mass spectrometry, and it is published under the batch number printed on the vial. You can search the certificate of analysis library by that batch number and match the report to the vial in your hand.

Given the 2025 review's warning about unregulated manufacturing and contamination, ^[6] the certificate is the part of the purchase that carries the evidence. The identity result should match a peptide of about 1419.5 g/mol, and our guide on how to read a peptide certificate of analysis explains the HPLC trace, the mass spectrum and net peptide content. The BPC-157 product page links the certificate for the current batch.

BPC-157 is a 15-residue synthetic peptide with a short half-life in animals, a large rodent literature and almost no controlled human data. About three in four PubMed records on it share one author, and the three human pilots together enrolled fewer than 30 people. In Australia it is a Schedule 4 substance listed in Appendix D clause 5, and WADA prohibits it at all times. For a research vial, the batch certificate is the evidence that settles what is inside.